-
As of late September 2025, new Alzheimer’s drugs like lecanemab and donanemab show promise in slowing disease progression but require early diagnosis and carry risks. The UK’s NHS and Australia face challenges in access and funding, while the UAE highlights the need for improved awareness and infrastructure. Meanwhile, the UK’s rollout of weight-loss drug Mounjaro is underfunded, limiting patient access amid rising demand and GP shortages.
-
On October 10, 2025, President Donald Trump announced a deal with AstraZeneca to lower drug prices for Medicaid patients by matching the lowest prices in developed countries. The agreement includes AstraZeneca's commitment to invest $50 billion in U.S. manufacturing by 2030 and participation in the upcoming TrumpRx website, which will sell discounted drugs directly to consumers starting in early 2026.
-
Major pharmaceutical firms have paused or canceled over £2bn in UK investments this year amid concerns over drug pricing policies, US pressure for price parity, and a deteriorating investment climate. Industry warnings highlight risks to future drug development and supply chains.
-
Former England rugby captain Lewis Moody has been diagnosed with amyotrophic lateral sclerosis (ALS). Despite minor symptoms, he remains positive and active. Moody, a World Cup winner and rugby legend, is focusing on staying strong while raising awareness and funds for research. The news has prompted tributes and support from the rugby community.
-
A woman in Hemel Hempstead received a stage 3 kidney disease diagnosis via NHS app without prior consultation, highlighting issues with digital health communication. Meanwhile, advances in genomic testing are enabling earlier detection of rare diseases, exemplified by a newborn with eye cancer and a legal case over talc-related cancer risks. These stories underscore the evolving landscape of health diagnostics and communication.
-
Recent studies highlight the health risks of ultra-processed foods (UPFs), linking them to obesity, cancer, heart disease, and depression. Experts warn that industry influence and weak policies hinder regulation, risking worsening global diet quality and health outcomes.
-
The UK government announced sweeping changes to immigration and asylum policies, including longer settlement wait times, stricter eligibility criteria, and temporary refugee status. High earners and NHS workers are fast-tracked, while others face waits up to 30 years. The reforms aim to control migration and reform public services.
-
The UK National Screening Committee is set to recommend targeted prostate cancer screening for high-risk groups, including men with BRCA mutations and Black men, amid ongoing debates over PSA test efficacy and potential harms of mass screening. The decision follows recent advocacy and new research trials.